Based on groundbreaking work by Dr. Corina Anastasaki demonstrating that an anti-seizure medication, called lamotrigine, blocks neurofibroma and optic glioma growth in Nf1 mouse models, a patent was awarded to Washington University. This new patent application, entitled “methods of treating cancer using neuronal activity inhibiting agents” (18/069,317) provides a paradigm shift in the management of optic gliomas and neurofibromas in individuals with NF1. This invention, as well as the research that brought it to fruition, was supported by the National Institute of Health grants (NS097211 and CA233164) to Dr. David Gutmann. A clinical trial for NF1 optic pathway glioma is currently under review with the NF Clinical Trials Consortium.